Trial Profile

An open-label, single arm, long term trial of Spesolimab treatment in patients with Palmoplantar Pustulosis (PPP) who have completed previous BI Spesolimab trials

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 22 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Spesolimab (Primary)
Indications Palmoplantar pustulosis
Focus Adverse reactions
Sponsors Boehringer Ingelheim

Most Recent Events

16 Jun 2023 This trial has been completed in Poland (End Date: 15 May 2023), according to European Clinical Trials Database record.
22 May 2023 This trial has been completed in Germany and Hungary (End Date: 15 May 2023), according to European Clinical Trials Database record.
16 May 2023 Status changed from active, no longer recruiting to discontinued.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com